160 related articles for article (PubMed ID: 37256503)
1. Greater Combined Reductions of HbA
Dungan KM; Bardtrum L; Christiansen E; Eliasson J; Mellbin L; Woo VC; Vilsbøll T
Diabetes Ther; 2023 Aug; 14(8):1415-1425. PubMed ID: 37256503
[TBL] [Abstract][Full Text] [Related]
2. Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Rosenstock J; Cariou B; Eliasson J; Frappin G; Kaltoft MS; Montanya E; Knop FK
Diabetes Obes Metab; 2024 Feb; 26(2):532-539. PubMed ID: 37935463
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
4. GREATER COMBINED REDUCTIONS IN HbA
Rodbard HW; Bellary S; Hramiak I; Seino Y; Silver R; Damgaard LH; Nayak G; Zacho J; Aroda VR
Endocr Pract; 2019 Jun; 25(6):589-597. PubMed ID: 30865526
[No Abstract] [Full Text] [Related]
5. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
[TBL] [Abstract][Full Text] [Related]
6. Oral Semaglutide Reduces HbA
Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
[TBL] [Abstract][Full Text] [Related]
7. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
8. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Aroda VR; Bauer R; Christiansen E; Haluzík M; Kallenbach K; Montanya E; Rosenstock J; Meier JJ
Diabetes Obes Metab; 2022 Jul; 24(7):1338-1350. PubMed ID: 35373893
[TBL] [Abstract][Full Text] [Related]
10. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
[TBL] [Abstract][Full Text] [Related]
11. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.
Araki E; Terauchi Y; Watada H; Deenadayalan S; Christiansen E; Horio H; Kadowaki T
Diabetes Obes Metab; 2021 Dec; 23(12):2785-2794. PubMed ID: 34472698
[TBL] [Abstract][Full Text] [Related]
13. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
Mosenzon O; Capehorn MS; De Remigis A; Rasmussen S; Weimers P; Rosenstock J
Cardiovasc Diabetol; 2022 Sep; 21(1):172. PubMed ID: 36056351
[TBL] [Abstract][Full Text] [Related]
14. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR;
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068
[TBL] [Abstract][Full Text] [Related]
17. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F
Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724
[TBL] [Abstract][Full Text] [Related]
18. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Napoli R; Berra C; Catarig AM; Di Loreto C; Donatiello E; Berentzen TL; Pitocco D; Giorgino F
Diabetes Obes Metab; 2023 Jun; 25(6):1658-1667. PubMed ID: 36789682
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.
Lee BW; Cho YM; Kim SG; Ko SH; Lim S; Dahaoui A; Jeong JS; Lim HJ; Yu JM
Diabetes Ther; 2024 Feb; 15(2):547-563. PubMed ID: 38236431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
